The Journal of Experimental Medicine
Aegean Conferences: 2009 Conferences
  Home | Help | Feedback | Subscriptions | Archive | Search | Table of Contents
Published online April 16, 2007
doi:10.1084/jem.20061120
The Journal of Experimental Medicine, Vol. 204, No. 5, 1037-1047
The Rockefeller University Press, 0022-1007 $30.00
© 2007 Aspord et al.
This Article
Right arrow Full Text
Right arrow Full Text (PDF, 4610K)
Right arrow PPT slides of all figures
Right arrow Alert me when this article is cited
Right arrow Citation Map
Services
Right arrow Email this article
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new content in the JEM
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Aspord, C.
Right arrow Articles by Palucka, A. K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Aspord, C.
Right arrow Articles by Palucka, A. K.
Related Collections
Right arrowRelated Article
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

ARTICLE

 Breast cancer instructs dendritic cells to prime interleukin 13–secreting CD4+ T cells that facilitate tumor development

Caroline Aspord1, Alexander Pedroza-Gonzalez1, Mike Gallegos1, Sasha Tindle1, Elizabeth C. Burton2, Dan Su2, Florentina Marches1, Jacques Banchereau1, and A. Karolina Palucka1

1 Baylor Institute for Immunology Research and Baylor National Institute of Allergy and Infectious Diseases Cooperative Center for Translational Research on Human Immunology and Biodefense and 2 Department of Pathology, Baylor University Medical Center, Dallas, TX 75204

CORRESPONDENCE A. Karolina Palucka: karolinp{at}baylorhealth.edu

We previously reported (Bell, D., P. Chomarat, D. Broyles, G. Netto, G.M. Harb, S. Lebecque, J. Valladeau, J. Davoust, K.A. Palucka, and J. Banchereau. 1999. J. Exp. Med. 190: 1417–1426) that breast cancer tumors are infiltrated with mature dendritic cells (DCs), which cluster with CD4+ T cells. We now show that CD4+ T cells infiltrating breast cancer tumors secrete type 1 (interferon {gamma}) as well as high levels of type 2 (interleukin [IL] 4 and IL-13) cytokines. Immunofluorescence staining of tissue sections revealed intense IL-13 staining on breast cancer cells. The expression of phosphorylated signal transducer and activator of transcription 6 in breast cancer cells suggests that IL-13 actually delivers signals to cancer cells. To determine the link between breast cancer, DCs, and CD4+ T cells, we implanted human breast cancer cell lines in nonobese diabetic/LtSz-scid/scid ß2 microglobulin–deficient mice engrafted with human CD34+ hematopoietic progenitor cells and autologous T cells. There, CD4+ T cells promote early tumor development. This is dependent on DCs and can be partially prevented by administration of IL-13 antagonists. Thus, breast cancer targets DCs to facilitate its development.

Abbreviations used: CRTH2, chemoattractant receptor– homologous molecule expressed on Th2 cells; HPC, hematopoietic progenitor cell; Humouse, humanized mouse; NOD/SCID/ß2m–/–, nonobese diabetic/LtSz-scid/scid ß2 microglobulin–deficient; pSTAT6, phosphorylated STAT6; rh, recombinant human.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?

Related Article

Breast cancer hijacks dendritic cells
Hema Bashyam
J. Exp. Med. 2007 204: 967a. [Full Text] [PDF]



This article has been cited by other articles:



  Home | Help | Feedback | Subscriptions | Archive | Search
TABLE OF CONTENTS